PAN-ED
Start date:March 2020 Main trial site:
Royal Infirmary of Edinburgh
The UK is facing serious challenges about how an already overstretched workforce will cope during the pandemic within the emergency care settings. This pressure can lead to substantial effects on the mental health of staff. Therefore, we need to evaluate how we will appropriately support staff in the UK, but we do not know what the best approach is.
ED staff regularly deal with emergencies and unpredictable, often traumatic, situations. As a result, ED staff are more likely to experience mental health problems such as anxiety, stress, secondary traumatic stress and are more likely to feel “burnout” than staff in other areas of healthcare. They are also less likely to access appropriate support. It is therefore paramount that we consider the wellbeing of this staff group during a uniquely challenging time such as that of the COVID 19 outbreak.
Therefore, the Pan-ED study will be administering a wellbeing questionnaire to ED staff in the preparation, peak and resolution phases of the COVID-19 pandemic. The ED staff are a multi-disciplined team involving nurses, doctors, radiographers, domestics and administrative staff members, and all will be invited to participate in the study. By completing this study, we aim to have a better understanding of how to support these staff and prepare for potential future pandemics.
Research Team
Emily Godden
Senior Research Nurse - Renal/Acute Medicine
Emma Moatt
Research Project Manager
Fraser Craig
Clinical Trial Assistant
More EMERGE Trials
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
IONA Study
Identification of Novel Psychoactive Substances (IONA)
ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study
ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.